IBDEI0H8 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7705,0)
 ;;=N03.9^^52^518^20
 ;;^UTILITY(U,$J,358.3,7705,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7705,1,3,0)
 ;;=3^Chr nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,7705,1,4,0)
 ;;=4^N03.9
 ;;^UTILITY(U,$J,358.3,7705,2)
 ;;=^5015530
 ;;^UTILITY(U,$J,358.3,7706,0)
 ;;=N04.0^^52^518^60
 ;;^UTILITY(U,$J,358.3,7706,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7706,1,3,0)
 ;;=3^Nephrotic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,7706,1,4,0)
 ;;=4^N04.0
 ;;^UTILITY(U,$J,358.3,7706,2)
 ;;=^5015531
 ;;^UTILITY(U,$J,358.3,7707,0)
 ;;=N04.1^^52^518^59
 ;;^UTILITY(U,$J,358.3,7707,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7707,1,3,0)
 ;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,7707,1,4,0)
 ;;=4^N04.1
 ;;^UTILITY(U,$J,358.3,7707,2)
 ;;=^5015532
 ;;^UTILITY(U,$J,358.3,7708,0)
 ;;=N04.2^^52^518^56
 ;;^UTILITY(U,$J,358.3,7708,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7708,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
 ;;^UTILITY(U,$J,358.3,7708,1,4,0)
 ;;=4^N04.2
 ;;^UTILITY(U,$J,358.3,7708,2)
 ;;=^5015533
 ;;^UTILITY(U,$J,358.3,7709,0)
 ;;=N04.3^^52^518^57
 ;;^UTILITY(U,$J,358.3,7709,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7709,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7709,1,4,0)
 ;;=4^N04.3
 ;;^UTILITY(U,$J,358.3,7709,2)
 ;;=^5015534
 ;;^UTILITY(U,$J,358.3,7710,0)
 ;;=N04.4^^52^518^55
 ;;^UTILITY(U,$J,358.3,7710,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7710,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7710,1,4,0)
 ;;=4^N04.4
 ;;^UTILITY(U,$J,358.3,7710,2)
 ;;=^5015535
 ;;^UTILITY(U,$J,358.3,7711,0)
 ;;=N04.5^^52^518^58
 ;;^UTILITY(U,$J,358.3,7711,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7711,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
 ;;^UTILITY(U,$J,358.3,7711,1,4,0)
 ;;=4^N04.5
 ;;^UTILITY(U,$J,358.3,7711,2)
 ;;=^5015536
 ;;^UTILITY(U,$J,358.3,7712,0)
 ;;=N04.6^^52^518^53
 ;;^UTILITY(U,$J,358.3,7712,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7712,1,3,0)
 ;;=3^Nephrotic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,7712,1,4,0)
 ;;=4^N04.6
 ;;^UTILITY(U,$J,358.3,7712,2)
 ;;=^5015537
 ;;^UTILITY(U,$J,358.3,7713,0)
 ;;=N04.7^^52^518^54
 ;;^UTILITY(U,$J,358.3,7713,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7713,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse crescentic glomerulonephritis
 ;;^UTILITY(U,$J,358.3,7713,1,4,0)
 ;;=4^N04.7
 ;;^UTILITY(U,$J,358.3,7713,2)
 ;;=^5015538
 ;;^UTILITY(U,$J,358.3,7714,0)
 ;;=N04.8^^52^518^61
 ;;^UTILITY(U,$J,358.3,7714,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7714,1,3,0)
 ;;=3^Nephrotic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,7714,1,4,0)
 ;;=4^N04.8
 ;;^UTILITY(U,$J,358.3,7714,2)
 ;;=^5015539
 ;;^UTILITY(U,$J,358.3,7715,0)
 ;;=N04.9^^52^518^62
 ;;^UTILITY(U,$J,358.3,7715,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7715,1,3,0)
 ;;=3^Nephrotic syndrome w/ unspecified morphologic changes
 ;;^UTILITY(U,$J,358.3,7715,1,4,0)
 ;;=4^N04.9
 ;;^UTILITY(U,$J,358.3,7715,2)
 ;;=^5015540
 ;;^UTILITY(U,$J,358.3,7716,0)
 ;;=N05.0^^52^518^50
 ;;^UTILITY(U,$J,358.3,7716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7716,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,7716,1,4,0)
 ;;=4^N05.0
 ;;^UTILITY(U,$J,358.3,7716,2)
 ;;=^5015541
 ;;^UTILITY(U,$J,358.3,7717,0)
 ;;=N05.1^^52^518^49
 ;;^UTILITY(U,$J,358.3,7717,1,0)
 ;;=^358.31IA^4^2
